As it is a urine test it is simpler and noninvasive compared to PSA and other tests which use serum.

Mutated version of PCADM-1 that will be used as the diagnostic marker for Procare’s tests is only produced by prostate cancer cells and not by healthy prostate cells. This makes it highly specific.

In clinical studies PCADM-1 has demonstrated a higher specificity and sensitivity in detection of prostate cancer compared to currently used tests such as PSA. PSA is triggered by AR(+), and there is evidence that AR(-) may be associated with metastasis and not detected by PSA. Consequently, this marker may be useful in determining whether androgen inhibitor therapy will be efficient.

Levels of PCADM-1 demonstrate correlation to Gleason Score, hence it provides information on the grade of cancer, until now only possible through biopsies.

As noted, this test is capable of detecting cancer comprising AR-negative cells which are undetectable by existing tests.